Lyra Therapeutics Inc(LYRA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 4:00 PM ET (Korea 10/24 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -22.9 | Insider Own | 0.62% | Shs Outstand | 1.8M | Perf Week | - |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | -91.53% | Shs Float | 0.4M | Perf Month | -64.64% |
| Enterprise Value | - | PEG | - | EPS next Q | - | Inst Own | 21.06% | Short Float | 11.66% | Perf Quarter | -86.1% |
| Income | - | P/S | 1.46 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.42 | Perf Half Y | -92.38% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.04M | Perf YTD | -83.93% |
| Book/sh | -2.63 | P/C | - | EPS past 3/5Y | 24.62% - | ROE | - | 52W High | -98.68% ($37.50) | Perf Year | -94.24% |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | 75.25% - | ROIC | - | 52W Low | 2.13% ($0.48) | Perf 3Y | -99.52% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 68.97% | Gross Margin | - | Volatility(W/M) | 39.44% 20.26% | Perf 5Y | -99.93% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -59.21% | Oper. Margin | - | ATR (14) | 0.21 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | - | Profit Margin | - | RSI (14) | 21.62 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | -87.2% | SMA20 | -61.1% ($1.29) | Beta | 0.32 | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | 2025/11/12 | SMA50 | -72.83% ($1.84) | Rel Volume | 0 | Prev Close | $0.5 |
| Employees | 30 | LT Debt/Eq | - | EPS/Sales Surpr. | 35.68% -87.85% | SMA200 | -91.68% ($6.01) | Avg Volume(3M) | 0.10M | Price | $0.5 |
| IPO | 2020/5/1 | Option/Short | No/Yes | Trades | 0 | Volume | - | Change | - |
🧬 Lyra Therapeutics (LYRA) is a next-generation biopharmaceutical company that researches and develops locally acting, long-acting clinical therapeutics for nasal and respiratory diseases—including chronic rhinosinusitis—by leveraging its proprietary elastic mesh precision drug delivery platform (XTreo).
Over the past 1 year, on the lower side
99% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $146. Peers typically go for $204.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 21.1%.
Tap to view numbers
It ranks #590 of 596 in the industry
Based on market cap of $1M.
BBLG#589 Bone Biologics Corp $1M PER - LYRA#590 Lyra Therapeutics Inc $1M PER - 
CRIS#590 Curis Inc $1M PER - 
LABT#591 Lakewood-Amedex Biotherapeutics Inc $1M PER - 
SPRC#592 SciSparc Ltd $1M PER - 
FAQ
What kind of company is LYRA?
LYRA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LYRA?
The market cap of LYRA is approximately $1M, ranking 5,839 within its sector.
What is the 52-week high and low for LYRA?
LYRA has recorded a 52-week high of $37.50 and a low of $0.48.
